



(11) **EP 1 933 833 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 31/4178** <sup>(2006.01)</sup> **A61K 31/216** <sup>(2006.01)</sup>  
**A61K 31/137** <sup>(2006.01)</sup> **A61K 31/439** <sup>(2006.01)</sup>  
**A61K 31/4025** <sup>(2006.01)</sup> **A61K 31/46** <sup>(2006.01)</sup>  
**A61K 31/00** <sup>(2006.01)</sup> **A61P 1/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**14.09.2011 Bulletin 2011/37**

(86) International application number:  
**PCT/US2006/033671**

(45) Date of publication and mention  
of the grant of the patent:  
**20.04.2011 Bulletin 2011/16**

(87) International publication number:  
**WO 2007/027675 (08.03.2007 Gazette 2007/10)**

(21) Application number: **06813885.8**

(22) Date of filing: **28.08.2006**

(54) **THERAPY FOR THE TREATMENT OF OVERACTIVE BLADDER**

THERAPIE ZUR BEHANDLUNG DER ÜBERAKTIVEN BLASE

THERAPIE POUR LE TRAITEMENT DE LA VESSIE HYPERACTIVE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI**  
**SK TR**

(30) Priority: **02.09.2005 US 714150 P**

(43) Date of publication of application:  
**25.06.2008 Bulletin 2008/26**

(73) Proprietor: **TheraVida, Inc.**  
**San Mateo, CA 94402 (US)**

(72) Inventor: **PABORJI, Mehdi**  
**Cupertino, California 95014 (US)**

(74) Representative: **Viering, Jentschura & Partner**  
**Postfach 22 14 43**  
**80504 München (DE)**

(56) References cited:

- **SALAH R S ET AL: "Pilocarpine for anticholinergic adverse effects associated with desipramine treatment [6]" AMERICAN JOURNAL OF PSYCHIATRY 1996 UNITED STATES, vol. 153, no. 4, 1996, page 579, XP009076441 ISSN: 0002-953X**
- **MASTERS KIM J: "Pilocarpine treatment of xerostomia induced by psychoactive medications" AMERICAN JOURNAL OF PSYCHIATRY, vol. 162, no. 5, May 2005 (2005-05), page 1023, XP002412730 ISSN: 0002-953X**
- **OKI TOMOMI ET AL: "Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice." BRITISH JOURNAL OF PHARMACOLOGY. MAY 2005, vol. 145, no. 2, May 2005 (2005-05), pages 219-227, XP002412731 ISSN: 0007-1188**
- **FOOTE JENELLE ET AL: "Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M-3 selective receptor antagonist" EUROPEAN UROLOGY, vol. 48, no. 3, September 2005 (2005-09), pages 471-477, XP002412732 ISSN: 0302-2838**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 933 833 B8**